-transparent.png){kind=logo}
We examined the effects of high-dose intravenous naloxone administration in four acromegalic patients (mean serum growth hormone level 72 ng/ml) and in seven hyperprolactinaemic women (mean serum prolactin level 59 ng/ml), in order to assess whether this opiate antagonist would be effective in lowering growth hormone and prolactin levels. No effect was observed. This lack of effect suggests that an opioid pathway is not involved in the maintenance of elevated growth hormone or prolactin secretion in these patients. However, conclusions regarding the possible role of endogenous opioids in regulation of pituitary function in normal individuals cannot be drawn from this study.
J Blankstein, and
F Reyes, and
J Winter, and
C Faiman
November 1980,
Clinical endocrinology,
J Blankstein, and
F Reyes, and
J Winter, and
C Faiman
January 1996,
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association,
J Blankstein, and
F Reyes, and
J Winter, and
C Faiman
January 1996,
Clinical endocrinology,
J Blankstein, and
F Reyes, and
J Winter, and
C Faiman
May 1979,
Brain research,
J Blankstein, and
F Reyes, and
J Winter, and
C Faiman
December 1976,
The Journal of clinical endocrinology and metabolism,
J Blankstein, and
F Reyes, and
J Winter, and
C Faiman
August 1976,
The Journal of clinical endocrinology and metabolism,
J Blankstein, and
F Reyes, and
J Winter, and
C Faiman
May 1983,
Acta endocrinologica,
J Blankstein, and
F Reyes, and
J Winter, and
C Faiman
January 1985,
European journal of clinical pharmacology,
J Blankstein, and
F Reyes, and
J Winter, and
C Faiman
March 1977,
The Journal of clinical endocrinology and metabolism,
J Blankstein, and
F Reyes, and
J Winter, and
C Faiman
July 1983,
Clinical pharmacology and therapeutics,
